Other News To Note
Tuesday, May 15, 2012
Biovest International Inc., a subsidiary of Accentia Biopharmaceuticals Inc., both of Tampa, Fla., said it plans to file a marketing authorization application with the European Medicines Agency (EMA) for BiovaxID, its personalized cancer vaccine in follicular non-Hodgkin's lymphoma, following pre-filing meetings with the EMA.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.